Bristol-Myers Squibb Company (BMY) Quick Ratio (Acid-Test): 1.14
Is Bristol-Myers Squibb Company’s quick ratio (acid-test) high or low?
Bristol-Myers Squibb Company's quick ratio (acid-test) of 1.14 is 10% below its 5-year average of 1.27, near the low end of its 5-year range (1.14–1.47).
The quick ratio (acid-test) for Bristol-Myers Squibb Company (BMY) is 1.14 as of Tuesday, June 9, 2026. It is below its 12-month average by 0.44% (1.15).
BMY Quick Ratio (Acid-Test) Chart
BMY Average Quick Ratio (Acid-Test) Chart
BMY Current vs Average Quick Ratio (Acid-Test) Chart
BMY Quick Ratio (Acid-Test) Metrics
QUICK RATIO (ACID-TEST)
1.14
QUICK RATIO (ACID-TEST) AVG TTM
1.15
QUICK RATIO (ACID-TEST) AVG 3Y
1.19
QUICK RATIO (ACID-TEST) AVG 5Y
1.27
QUICK RATIO (ACID-TEST) AVG 10Y
1.32
QUICK RATIO (ACID-TEST) AVG 15Y
1.38
QUICK RATIO (ACID-TEST) AVG 20Y
1.41
CURRENT VS TTM AVG
-0.44%
CURRENT VS 3Y AVG
-3.80%
CURRENT VS 5Y AVG
-10.47%
CURRENT VS 10Y AVG
-13.81%
CURRENT VS 15Y AVG
-17.17%
CURRENT VS 20Y AVG
-19.23%
BMY Competitors' Quick Ratio (Acid-Test)
| NAME | MARKET CAP | QUICK RATIO (ACID-TEST) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Bristol-Myers Squibb Company (BMY) | — | 1.14 | 1.15 | 1.19 | 1.27 |
| Vertex Pharmaceuticals Incorporated (VRTX) | $110.77B | 2.46 | 2.41 | 3.31 | 3.62 |
| CVS Health Corporation (CVS) | $123.84B | 0.63 | 0.61 | 0.63 | 0.63 |
| Medtronic plc (MDT) | $105.25B | 0.00 | 1.48 | 1.57 | 1.68 |
| Danaher Corporation (DHR) | $133.37B | 1.51 | 1.28 | 1.37 | 1.36 |
| Elevance Health Inc. (ELV) | $92.17B | 1.24 | 1.17 | 1.08 | 1.07 |
| Pfizer Inc. (PFE) | $146.48B | 0.87 | 0.90 | 0.87 | 0.95 |
| Intuitive Surgical, Inc. (ISRG) | $151.09B | 3.96 | 3.59 | 3.74 | 4.30 |
| Cigna Corporation (CI) | $78.04B | 0.72 | 0.72 | 0.68 | 0.69 |
| Gilead Sciences, Inc. (GILD) | $155.82B | 1.31 | 1.38 | 1.29 | 1.26 |
Liquidity Comparison
Quick Ratio
1.14
Excludes inventory
Current Ratio
1.26
Includes inventory
Bristol-Myers Squibb Company Quick Ratio (Acid-Test) Formula & Definition
Quick Ratio = (Current Assets − Inventory) / Current Liabilities
The quick ratio is a stricter liquidity measure that excludes inventory, showing the ability to meet short-term obligations with the most liquid assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Bristol-Myers Squibb Company Quick Ratio (Acid-Test) FAQ
- What is the quick ratio (acid-test) for Bristol-Myers Squibb Company (BMY)?
- The quick ratio (acid-test) for BMY stock is 1.14.
- Is Bristol-Myers Squibb Company's quick ratio (acid-test) high or low?
- Bristol-Myers Squibb Company's quick ratio (acid-test) of 1.14 is 10% below its 5-year average of 1.27, near the low end of its 5-year range (1.14–1.47).
- What is the TTM average quick ratio (acid-test) for Bristol-Myers Squibb Company (BMY)?
- The TTM average quick ratio (acid-test) for BMY stock is 1.15.
- What is the 3Y average quick ratio (acid-test) for Bristol-Myers Squibb Company (BMY)?
- The 3Y average quick ratio (acid-test) for BMY stock is 1.19.
- What is the 5Y average quick ratio (acid-test) for Bristol-Myers Squibb Company (BMY)?
- The 5Y average quick ratio (acid-test) for BMY stock is 1.27.
- What is the 10Y average quick ratio (acid-test) for Bristol-Myers Squibb Company (BMY)?
- The 10Y average quick ratio (acid-test) for BMY stock is 1.32.
- What is the 15Y average quick ratio (acid-test) for Bristol-Myers Squibb Company (BMY)?
- The 15Y average quick ratio (acid-test) for BMY stock is 1.38.
- What is the 20Y average quick ratio (acid-test) for Bristol-Myers Squibb Company (BMY)?
- The 20Y average quick ratio (acid-test) for BMY stock is 1.41.
Bristol-Myers Squibb Company Quick Ratio (Acid-Test) History
| DATE | QUICK RATIO (ACID-TEST) |
|---|---|
| 2025-12-31 | 1.14 |
| 2024-12-31 | 1.15 |
| 2023-12-31 | 1.31 |
| 2022-12-31 | 1.14 |
| 2021-12-31 | 1.43 |
| 2020-12-31 | 1.47 |
| 2019-12-31 | 1.37 |
| 2018-12-31 | 1.55 |
| 2017-12-31 | 1.43 |
| 2016-12-31 | 1.41 |
| 2015-12-31 | 1.15 |
| 2014-12-31 | 1.54 |
| 2013-12-31 | 1.40 |
| 2012-12-31 | 0.95 |
| 2011-12-31 | 1.79 |
| 2010-12-31 | 1.79 |
| 2009-12-31 | 1.99 |
| 2008-12-31 | 1.93 |
| 2007-12-31 | 0.95 |
| 2006-12-31 | 1.27 |
| 2005-12-31 | 1.48 |
| 2004-12-31 | 1.32 |
| 2003-12-31 | 1.39 |
| 2002-12-31 | 1.00 |
| 2001-12-31 | 1.04 |
| 2000-12-31 | 1.42 |
| 1999-12-31 | 1.29 |
| 1998-12-31 | 1.19 |
| 1997-12-31 | 1.18 |
| 1996-12-31 | 1.16 |
Related Metrics
About Bristol-Myers Squibb Company
Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations. Founded in 1887 and formerly known as Bristol-Myers Company, the firm maintains its headquarters in New York, New York.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Christopher S. Boerner